Close Window

Digital Look Email A Friend

Astrazeneca secures US approval for Truqap combo in PTEN‑deficient prostate cancer

Published by Iain Gilbert on 15th June 2026

(Sharecast News) - Drugmaker Astrazeneca said on Monday that its cancer drug Truqap, used with abiraterone and prednisone, has been approved in the US as the first targeted treatment for a form of advanced prostate cancer driven by a fault in the PTEN gene.

URL: http://www.digitallook.com/dl/news/story/36000137/...

Email this article to your friends
NOTE: These email addresses will be used to email the information on your behalf and will not be collected by Digital Look for any marketing purposes.